RxDoctor Payments Data

Rachel Sims

Registered Nurse · Fort Myers, FLNPI 1245860410

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 374 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,408, 5.6 times the $429 reported in 2021. Among registered nurse clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,071in general payments, 2019–2025

Across 374 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$760
  • Amgen$494
  • AstraZeneca$473
  • Neurocrine Biosciences, Inc.$473
  • Acadia Pharmaceuticals Inc$418
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,040100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,071 in reported general payments places this provider in the 95th percentile of 185 registered nurse providers in Florida.

See all registered nurse providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4618$215,707
Austedo XrDeutetrabenazine19$103,601
NuplazidPimavanserin Tartrate17$80,619
GocovriAmantadine Hcl27$64,303
QuliptaAtogepant28$54,399
Emgality PenGalcanezumab-Gnlm63$54,035
NourianzIstradefylline15$43,339
Nurtec OdtRimegepant Sulfate35$39,985
RytaryCarbidopa/Levodopa26$38,269
BriviactBrivaracetam21$35,891
UbrelvyUbrogepant30$34,303
Ajovy SyringeFremanezumab-Vfrm17$15,374
Emgality SyringeGalcanezumab-Gnlm13$12,193
Aimovig AutoinjectorErenumab-Aooe12$12,104
Lacosamide71$11,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$99$103,60119 claims
AbbVieQulipta, Ubrelvy$1,039$88,70258 claims
Acadia Pharmaceuticals IncNuplazid$418$80,61917 claims
Kyowa Kirin, Inc.Nourianz$43$43,33915 claims
PfizerNurtec Odt$234$39,98535 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$73$39,79046 claims
UCB, Inc.Briviact$760$35,89121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 185 registered nurse providers in Florida.

Other registered nurse in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →